title: Is immunotherapy an opportunity for effective treatment of drug addiction?
abstract: Immunotherapy has a great potential of becoming a new therapeutic strategy in the treatment of addiction to psychoactive drugs. It may be used to treat addiction but also to prevent neurotoxic complications of drug overdose. In preclinical studies two immunological methods have been tested; active immunization, which relies on the administration of vaccines and passive immunization, which relies on the administration of monoclonal antibodies. Until now researchers have succeeded in developing vaccines and/or antibodies against addiction to heroin, cocaine, methamphetamine, nicotine and phencyclidine. Their effectiveness has been confirmed in preclinical studies. At present, clinical studies are being conducted for vaccines against nicotine and cocaine and also anti-methamphetamine monoclonal antibody. These preclinical and clinical studies suggest that immunotherapy may be useful in the treatment of addiction and drug overdose. However, there are a few problems to be solved. One of them is controlling the level of antibodies due to variability between subjects. But even obtaining a suitable antibody titer does not guarantee the effectiveness of the vaccine. Additionally, there is a risk of intentional or unintentional overdose. As vaccines prevent passing of drugs through the blood/brain barrier and thereby prevent their positive reinforcement, some addicted patients may erroneously seek higher doses of psychoactive substances to get "high". Consequently, vaccination should be targeted at persons who have a strong motivation to free themselves from drug dependency. It seems that immunotherapy may be an opportunity for effective treatment of drug addiction if directed to adequate candidates for treatment. For other addicts, immunotherapy may be a very important element supporting psycho- and pharmacotherapy.
authors.affiliation: Department of Pharmacodynamics, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland. Electronic address: jadwiga.zalewska-kaszubska@umed.lodz.pl.
authors.forename: Jadwiga
authors.initials: J
authors.lastname: Zalewska-Kaszubska
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003042:Cocaine / Q000276:immunology; D005260:Female; D003932:Heroin / Q000276:immunology; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D008297:Male; D009538:Nicotine / Q000276:immunology; D019966:Substance-Related Disorders / Q000276:immunology* / Q000628:therapy*; D016896:Treatment Outcome; D014611:Vaccination / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D009538:Nicotine; D003932:Heroin; D003042:Cocaine
keywords: Addiction; Antibody; Cocaine; Methamphetamine; Nicotine; Opioid; Phencyclidine; Vaccine